Literature DB >> 28266522

Getting real about NCI-designated Cancer Center advertising.

David Rubenson1, Daniel S Kapp2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28266522     DOI： 10.1038/nrclinonc.2017.28

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Advertising by academic medical centers.

Authors:  Robin J Larson; Lisa M Schwartz; Steven Woloshin; H Gilbert Welch
Journal:  Arch Intern Med       Date:  2005-03-28

2.  Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.

Authors:  Tito Fojo; Sham Mailankody; Andrew Lo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-12       Impact factor: 6.223

Review 3.  Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery.

Authors:  G A Gooiker; W van Gijn; M W J M Wouters; P N Post; C J H van de Velde; R A E M Tollenaar
Journal:  Br J Surg       Date:  2011-04       Impact factor: 6.939

4.  Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.

Authors:  Saroj Niraula; Eitan Amir; Francisco Vera-Badillo; Bostjan Seruga; Alberto Ocana; Ian F Tannock
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

5.  Trends in Cancer-Center Spending on Advertising in the United States, 2005 to 2014.

Authors:  Laura B Vater; Julie M Donohue; Seo Young Park; Yael Schenker
Journal:  JAMA Intern Med       Date:  2016-08-01       Impact factor: 21.873

Review 6.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Authors:  Ignacio Garrido-Laguna; Manuel Hidalgo
Journal:  Nat Rev Clin Oncol       Date:  2015-03-31       Impact factor: 66.675

7.  Cancer Center Advertising-Where Hope Meets Hype.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  JAMA Intern Med       Date:  2016-08-01       Impact factor: 21.873

8.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Authors:  Hannah Bower; Magnus Björkholm; Paul W Dickman; Martin Höglund; Paul C Lambert; Therese M-L Andersson
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

9.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

Review 10.  Characteristics of Exceptional or Super Responders to Cancer Drugs.

Authors:  Vinay Prasad; Andrae Vandross
Journal:  Mayo Clin Proc       Date:  2015-11-03       Impact factor: 7.616
  10 in total
  1 in total

1.  Online advertising and marketing claims by providers of proton beam therapy: are they guideline-based?

Authors:  Mark T Corkum; Wei Liu; David A Palma; Glenn S Bauman; Robert E Dinniwell; Andrew Warner; Mark V Mishra; Alexander V Louie
Journal:  Radiat Oncol       Date:  2018-03-15       Impact factor: 3.481
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.